This Event has Passed
Monday, March 18, 2024 - 9:00 AM
to Wednesday, March 20, 2024 - 3:30 PM
9:00 AM - 3:30 PM See all dates and Times
The 7th Antigen-Specific Immune Tolerance Drug Development Summit returns as the definitive, industry-dedicated forum bringing you the latest discoveries, preclinical, proof-of-concept, biomarker, and clinical development on tolerogenic therapies.
Immune tolerance approaches have unprecedented potential to not only treat autoimmune diseases but to cure them; resetting the immune system is the most advantageous approach in biopharma’s arsenal to trailblaze past standard immunosuppression treatments and create a new era of transformative therapies.
With Diamyd’s phase III trial for type I diabetes, COUR, Anokion, Imcyse, Takeda, and Selecta’s phase II trials all underway, the field is on the precipice of advancing efficacious antigen-specific approaches for patients in need.
Event Links
Website: https://go.evvnt.com/2063192-0
Tickets: https://go.evvnt.com/2063192-2
Brochure: https://go.evvnt.com/2063192-3
